The US FDA has renewed its risk approval order for the first time: eight Swedish match snuff products can be sold until 2032

The US FDA has renewed its risk approval order for the first time: eight Swedish match snuff products can be sold until 2032

The US FDA announced the renewal of risk correction authorization for eight generic snuff products from Swedish Match, allowing them to continue selling until 2032. These products have obtained a declaration that "using snuff instead of cigarettes can reduce the risk of various diseases", including oral cancer, heart disease, and lung cancer. The FDA emphasizes that the renewal is based on scientific evidence and confirms the harm reducing effect of snuff.

On November 7th, US time, the US Food and Drug Administration (FDA) announced on its official website that after rigorous scientific review, it has issued a modified risk authorization renewal order to Swedish Match USA, Inc. for eight generic snuff products. Through this renewal, these products can continue to be sold (they have been approved for sale since 2019) and come with the following modified risk statement: "Using generic snuff instead of cigarettes can reduce the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis

The products that have obtained risk correction orders include:

General Loose
General Dry Mint Portion Original Mini
General Portion Original Large
General Classic Blend Portion White Large-12ct
General Mint Portion White Large
General Nordic Mint Portion White Large-12ct
General Portion White Large
General Wintergreen Portion White Large.

The risk correction order issued by the FDA specifically targets the above-mentioned products and is valid until November 7, 2032. If the agency determines at any time that, among other things, continuing to sell these products is no longer beneficial to the health of the entire population, the agency may withdraw the order.

The FDA stated that the review determined that this risk reduction statement is supported by scientific evidence, that consumers understand the statement, and that consumers correctly recognize the relative risks of these products compared to cigarettes. The FDA has found that these risk reducing products, when actually used by consumers, will greatly reduce the harm to tobacco users and the risk of tobacco related diseases, and benefit the health of the entire population. Especially, existing scientific evidence, including long-term epidemiological studies, suggests that specialized use of these products can reduce the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis compared to smoking. The existing evidence does not indicate that a large number of teenagers have started using these products.

The FDA emphasizes that the modified risk allocation order does not allow the company to market the product with any other modified risk statements that convey or may mislead consumers into believing that the product has been approved or approved by the FDA, or that the FDA considers the product safe for consumers. People who do not use tobacco products should not start using them without safe tobacco products.

The FDA stated that this is the first time the FDA has renewed or modified a risk approval order.

These products were initially approved for external link disclaimer in 2015, and were launched in the United States through the pre-market tobacco product application process.
In October 2019, the product was authorized to be sold as an improved risk tobacco product with an external link disclaimer.
The order allowing ordinary snuff products to be sold as improved risk tobacco products in 2019 is valid for 5 years.
In order to continue selling these products after the deadline specified in the 2019 order, Sweden Match has submitted a renewal application for improved risk tobacco products.

Revise Risk Approval Order | Image Source: FDA